Back to School: How biopharma can reboot drug development. Access exclusive analysis here

RIP Mark Schoenebaum, treasured biopharma analyst

Mark Schoenebaum, an admired biopharma equity analyst, died over the weekend.

Schoenebaum resigned as senior managing director and head of healthcare/biotech & pharma

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE